Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find - 2Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- 35 VIP Voice Exhibitions in Energized Movies
- 4Scientists find evidence that an asteroid contains tryptophan
- 5AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Japan deploys the military to counter a surge in bear attacks
- Select Your Go-To Bluetooth Earphones
- Bavarian leader questions Germany's Eurovision participation
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- The Specialty of Compromise: Examples from Reality
